215 related articles for article (PubMed ID: 16932707)
1. Efficacy and safety of infliximab for the treatment of psoriatic arthritis.
Ritchlin C
Nat Clin Pract Rheumatol; 2006 Jun; 2(6):300-1. PubMed ID: 16932707
[No Abstract] [Full Text] [Related]
2. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha.
Conti F; Ceccarelli F; Priori R; Iagnocco A; Signore A; Valesini G
Ann Rheum Dis; 2008 Dec; 67(12):1787-90. PubMed ID: 19005158
[No Abstract] [Full Text] [Related]
3. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al.
Cisternas M; Gutiérrez M; Jacobelli S
Arthritis Rheum; 2002 Nov; 46(11):3107-8; author reply 3108-9. PubMed ID: 12428265
[No Abstract] [Full Text] [Related]
4. Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy.
Izzi S; Francesconi F; Visca P; Altieri A; De Mutiis C; Trevisan G; Bonifati C
Dermatol Online J; 2010 May; 16(5):16. PubMed ID: 20492833
[TBL] [Abstract][Full Text] [Related]
5. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment.
Nikas SN; Voulgari PV; Takalou IP; Katsimbri P; Drosos AA
Ann Rheum Dis; 2005 Nov; 64(11):1665-7. PubMed ID: 16227426
[No Abstract] [Full Text] [Related]
6. [Infliximab].
Herrera E; Habicheyn S
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():7-13. PubMed ID: 19080986
[TBL] [Abstract][Full Text] [Related]
7. Psoriatic arthritis patients doing better on infliximab than etanercept.
Smith N; Gadsby K; Deighton C
Rheumatology (Oxford); 2007 Apr; 46(4):721-2. PubMed ID: 17314216
[No Abstract] [Full Text] [Related]
8. Long term treatment of psoriatic arthritis with infliximab.
Yazdani-Biuki B; Wohlfahrt K; Mulabecirovic A; Mueller T; Hermann J; Graninger WB; Brezinschek HP; Brezinschek RI
Ann Rheum Dis; 2004 Nov; 63(11):1531-2; author reply 1532. PubMed ID: 15479917
[No Abstract] [Full Text] [Related]
9. Long term infliximab treatment for severe psoriatic arthritis: evidence of sustained clinical and radiographic response.
Rinaldi F; Provenzano G; Termini A; Spinello M; La Seta F
Ann Rheum Dis; 2005 Sep; 64(9):1375-6. PubMed ID: 16100346
[No Abstract] [Full Text] [Related]
10. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study.
Voulgari PV; Venetsanopoulou AI; Exarchou SA; Alamanos Y; Tsifetaki N; Drosos AA
Semin Arthritis Rheum; 2008 Apr; 37(5):293-8. PubMed ID: 17888499
[TBL] [Abstract][Full Text] [Related]
11. Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo.
Vander Cruyssen B; De Keyser F; Kruithof E; Mielants H; Van den Bosch F
Ann Rheum Dis; 2007 Jan; 66(1):138-40. PubMed ID: 17178763
[No Abstract] [Full Text] [Related]
12. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab.
Bartke U; Venten I; Kreuter A; Gubbay S; Altmeyer P; Brockmeyer NH
Br J Dermatol; 2004 Apr; 150(4):784-6. PubMed ID: 15099388
[No Abstract] [Full Text] [Related]
13. Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.
Glintborg B; Gudbjornsson B; Krogh NS; Omerovic E; Manilo N; Holland-Fischer M; Lindegaard HM; Loft AG; Nordin H; Johnsen L; Oeftiger SF; Hansen A; Rasmussen C; Grondal G; Geirsson AJ; Hetland ML
Rheumatology (Oxford); 2014 Nov; 53(11):2100-9. PubMed ID: 24939677
[TBL] [Abstract][Full Text] [Related]
14. [Therapy of psoriasis-arthritis and psoriasis vulgaris with infliximab].
Mrowietz U; Barth J; Boehncke WH; Reich K; Rosenbach T; Streit V; Wozel G
J Dtsch Dermatol Ges; 2006 May; 4(5):444-7. PubMed ID: 16686615
[No Abstract] [Full Text] [Related]
15. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
[TBL] [Abstract][Full Text] [Related]
16. Infliximab: new indication. Psoriatic arthritis: just another intravenous me-too drug.
Prescrire Int; 2007 Oct; 16(91):188. PubMed ID: 17926824
[TBL] [Abstract][Full Text] [Related]
17. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
[TBL] [Abstract][Full Text] [Related]
18. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE.
van Vollenhoven RF; Klareskog L
Scand J Rheumatol; 2007; 36(6):418-23. PubMed ID: 18092261
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with multiple intra-articular injections of infliximab in a patient with psoriatic arthritis.
Alstergren P; Larsson PT; Kopp S
Scand J Rheumatol; 2008; 37(2):155-7. PubMed ID: 18415775
[TBL] [Abstract][Full Text] [Related]
20. Multidisciplinary focus on methotrexate in psoriatic disesase.
Marchesoni A; Ricci M; Moggio E; Brazzelli V; Borroni G
J Rheumatol Suppl; 2009 Aug; 83():56-8. PubMed ID: 19661543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
